CWM
IKT icon

CCG Wealth Management’s Inhibikase Therapeutics IKT Stock Holding History

CCG Wealth Management’s Portfolio IKT Stock Details IKT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$40.5K Buy
+24,118
New +$42.8K 0.01% 132
2023
Q2 		– Sell
-5,000
Closed -$19.7K – 67
2023
Q1 		$19.7K Hold
5,000
– – 0.01% 62
2022
Q4 		$15K Buy
5,000
+1,667
+50% +$6.61K 0.01% 101
2022
Q3 		$18K Buy
+3,333
New +$17.5K 0.01% 95

Other funds holding IKT

SCV
Sands Capital Ventures Arlington, Virginia $421M AUM 26.25% 1-Year Est. Return
SCM
Soleus Capital Management Greenwich, Connecticut $2.47B AUM 115.63% 1-Year Est. Return
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.38B AUM 407.79% 1-Year Est. Return
TECP
Trails Edge Capital Partners Atlanta, Georgia $437M AUM
ACM
ADAR1 Capital Management Austin, Texas $1.7B AUM 340.85% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Blackstone Inc
Blackstone Inc New York $25.6B AUM 26.83% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $3.61B AUM 203.3% 1-Year Est. Return
CC
Commodore Capital New York $1.73B AUM 298.96% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

CCG Wealth Management's IKT Position: Q1 2026 in Review

CCG Wealth Management opened a new position in Inhibikase Therapeutics (IKT) in Q1 2026: 24,118 shares worth $40.5K. The stake represents 0.01% of the portfolio and ranks #132 among its holdings. This is a return to the name: CCG Wealth Management previously reported a position in IKT as recently as Q1 2023.

CCG Wealth Management first reported a position in IKT in Q3 2022 and has held it in 4 quarters since. 104 funds tracked by Wall St. Rank hold IKT as of Q1 2026.

  • CCG Wealth Management held 24,118 shares of Inhibikase Therapeutics worth $40.5K as of Q1 2026.
  • Inhibikase Therapeutics was a new CCG Wealth Management position in Q1 2026.
  • Inhibikase Therapeutics made up 0.01% of CCG Wealth Management's portfolio in Q1 2026, its #132 holding.
  • CCG Wealth Management first reported a position in Inhibikase Therapeutics in Q3 2022 and has held it in 4 quarters since.
  • 104 funds tracked by Wall St. Rank held Inhibikase Therapeutics as of Q1 2026.

Based on CCG Wealth Management's 13F filing for Q1 2026, filed 8 Apr 2026.